Literature DB >> 3501187

Rationale for the selection of ricin A-chain anti-T immunotoxins for mature T cell depletion.

J M Derocq1, G Laurent, P Casellas, H Vidal, P Poncelet, A Fauser, C Demur, F Jansen.   

Abstract

A series of 25 different ricin A-chain immunotoxins (IT) were prepared with monoclonal antibodies reacting with several T cell antigens belonging to different clusters of differentiation (CD) to select the most appropriate immunotoxins (IT) for mature T cell depletion. Our screening procedure was performed in 2 steps. First, IT were evaluated using protein synthesis inhibition assay on clonogenic malignant cells in order to determine the most active IT for a given CD. Second, IT thus selected were evaluated for both mature T cell killing efficacy and tolerance on hematopoietic progenitor cells (HPC). This study showed that (1) different IT directed against the same CD antigen displayed a wide range of activity, suggesting the need for a large screening of IT to determine the most appropriate antibody for a given target antigen; (2) anti-CD3 and anti-CD5 ricin A-chain IT are the most active, displaying a cytoreduction of more than 2 logs on mature T cells; (3) the 3 different anti-CD2 ricin A-chain IT evaluated in this study induced poor mature T cell cytoreduction despite their relative efficacy on leukemic cells; (4) anti-CD8 ricin A-chain IT showed almost no efficacy on relevant target cells; (5) no toxicity on HPC was found for concentrations up to 10(-8) of A-chain whatever the IT used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501187     DOI: 10.1097/00007890-198712000-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.

Authors:  R A Rasmussen; S L Counts; J M Lambert; A R Collinson
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.

Authors:  M Chiron; J P Jaffrezou; P Carayon; C Bordier; F Roubinet; C Xavier; M Brandely; G Laurent
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Authors:  Christoph Groth; Lenneke F J van Groningen; Tiago R Matos; Manita E Bremmers; Frank W M B Preijers; Harry Dolstra; Christian Reicherts; Nicolaas P M Schaap; Eric H G van Hooren; Joanna IntHout; Rosalinde Masereeuw; Mihai G Netea; John E Levine; George Morales; James L Ferrara; Nicole M A Blijlevens; Ypke V J M van Oosterhout; Matthias Stelljes; Walter J F M van der Velden
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-03       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.